Interpace Biosciences, Inc.
IDXG
$1.04
-$0.10-8.77%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 242.99% | 454.24% | 125.96% | 110.70% | 108.90% |
| Total Depreciation and Amortization | -53.28% | -73.33% | -70.41% | -60.72% | -54.28% |
| Total Amortization of Deferred Charges | -- | -100.00% | -75.44% | -56.25% | -30.00% |
| Total Other Non-Cash Items | -38.89% | -57.07% | -93.36% | -90.73% | -90.29% |
| Change in Net Operating Assets | -197.65% | -151.45% | 53.07% | 44.79% | 69.06% |
| Cash from Operations | 22.62% | 93.93% | 281.73% | 148.97% | 149.26% |
| Capital Expenditure | -86.38% | -69.66% | -25.97% | -17.66% | -45.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -92.20% | -94.13% | -94.13% |
| Cash from Investing | -906.90% | 14.85% | -100.32% | -100.81% | -101.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -124.00% | -64.00% | -310.00% | -833.33% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -43.75% | 70.37% | 70.37% | 70.37% | 70.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.56% | -- | -- | -- | -- |
| Cash from Financing | -15.40% | -154.49% | -526.25% | -424.92% | -267.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.16% | -128.58% | -203.24% | -211.54% | -187.85% |